Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.55
ARIA's Cash to Debt is ranked lower than
87% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ARIA: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
ARIA' s Cash to Debt Range Over the Past 10 Years
Min: 0.55  Med: 6.32 Max: 24.17
Current: 0.55
0.55
24.17
Equity to Asset -0.19
ARIA's Equity to Asset is ranked lower than
95% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARIA: -0.19 )
Ranked among companies with meaningful Equity to Asset only.
ARIA' s Equity to Asset Range Over the Past 10 Years
Min: -1.37  Med: 0.60 Max: 0.84
Current: -0.19
-1.37
0.84
F-Score: 3
Z-Score: -3.21
M-Score: -2.43
WACC vs ROIC
11.80%
-231.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -182.89
ARIA's Operating margin (%) is ranked lower than
61% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. ARIA: -182.89 )
Ranked among companies with meaningful Operating margin (%) only.
ARIA' s Operating margin (%) Range Over the Past 10 Years
Min: -36749.1  Med: -734.05 Max: 58.61
Current: -182.89
-36749.1
58.61
Net-margin (%) -194.57
ARIA's Net-margin (%) is ranked lower than
61% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. ARIA: -194.57 )
Ranked among companies with meaningful Net-margin (%) only.
ARIA' s Net-margin (%) Range Over the Past 10 Years
Min: -39582.8  Med: -782.73 Max: 47.63
Current: -194.57
-39582.8
47.63
ROA (%) -40.56
ARIA's ROA (%) is ranked lower than
64% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. ARIA: -40.56 )
Ranked among companies with meaningful ROA (%) only.
ARIA' s ROA (%) Range Over the Past 10 Years
Min: -120.13  Med: -80.44 Max: 92.14
Current: -40.56
-120.13
92.14
ROC (Joel Greenblatt) (%) -94.83
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ARIA: -94.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARIA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3088.06  Med: -884.82 Max: 1329.95
Current: -94.83
-3088.06
1329.95
Revenue Growth (3Y)(%) 494.40
ARIA's Revenue Growth (3Y)(%) is ranked higher than
100% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARIA: 494.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARIA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 23.70 Max: 494.4
Current: 494.4
0
494.4
EBITDA Growth (3Y)(%) -5.70
ARIA's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ARIA: -5.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARIA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.9  Med: 4.80 Max: 27.3
Current: -5.7
-17.9
27.3
EPS Growth (3Y)(%) -2.90
ARIA's EPS Growth (3Y)(%) is ranked higher than
50% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ARIA: -2.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARIA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.5  Med: -1.90 Max: 25.1
Current: -2.9
-18.5
25.1
» ARIA's 10-Y Financials

Financials (Next Earnings Date: 2016-05-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ARIA Guru Trades in Q1 2015

Joel Greenblatt 16,344 sh (New)
Michael Price 550,000 sh (New)
Jim Simons 2,675,481 sh (+850.84%)
Chuck Royce 375,352 sh (-14.81%)
Paul Tudor Jones 15,595 sh (-42.72%)
» More
Q2 2015

ARIA Guru Trades in Q2 2015

Chuck Royce 375,352 sh (unchged)
Michael Price 550,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 13,545 sh (-13.15%)
Jim Simons 2,094,481 sh (-21.72%)
» More
Q3 2015

ARIA Guru Trades in Q3 2015

Michael Price 716,500 sh (+30.27%)
Chuck Royce 375,352 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 23,639 sh (-98.87%)
» More
Q4 2015

ARIA Guru Trades in Q4 2015

Paul Tudor Jones 19,669 sh (New)
Jim Simons 776,881 sh (+3186.44%)
Michael Price 820,000 sh (+14.45%)
Chuck Royce 375,352 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about ARIAD Pharmaceuticals Inc

Michael Price Invests in 11 Companies in First Quarter
Value investor Michael Price (Trades, Portfolio) is known for acquiring stock in out-of-favor small cap companies that are believed to be good values. His approach has paid off: Today, he manages MFP Investors, with $1.6 billion under management, much of it his own money. Read more...

Ratios

vs
industry
vs
history
P/S 10.70
ARIA's P/S is ranked lower than
52% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. ARIA: 10.70 )
Ranked among companies with meaningful P/S only.
ARIA' s P/S Range Over the Past 10 Years
Min: 1.7  Med: 38.86 Max: 5517.5
Current: 10.7
1.7
5517.5
EV-to-EBIT -6.79
ARIA's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. ARIA: -6.79 )
Ranked among companies with meaningful EV-to-EBIT only.
ARIA' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.8  Med: -6.00 Max: 12.5
Current: -6.79
-18.8
12.5
EV-to-EBITDA -7.21
ARIA's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. ARIA: -7.21 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARIA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.2  Med: -6.50 Max: 11.7
Current: -7.21
-20.2
11.7
Current Ratio 2.08
ARIA's Current Ratio is ranked lower than
76% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ARIA: 2.08 )
Ranked among companies with meaningful Current Ratio only.
ARIA' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 3.80 Max: 12.12
Current: 2.08
1.22
12.12
Quick Ratio 2.07
ARIA's Quick Ratio is ranked lower than
71% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ARIA: 2.07 )
Ranked among companies with meaningful Quick Ratio only.
ARIA' s Quick Ratio Range Over the Past 10 Years
Min: 1.22  Med: 3.69 Max: 12.12
Current: 2.07
1.22
12.12
Days Inventory 194.14
ARIA's Days Inventory is ranked lower than
70% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. ARIA: 194.14 )
Ranked among companies with meaningful Days Inventory only.
ARIA' s Days Inventory Range Over the Past 10 Years
Min: 8.07  Med: 48.84 Max: 179.13
Current: 194.14
8.07
179.13
Days Sales Outstanding 48.19
ARIA's Days Sales Outstanding is ranked higher than
65% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. ARIA: 48.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARIA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.49  Med: 29.08 Max: 287.59
Current: 48.19
0.49
287.59
Days Payable 2.00
ARIA's Days Payable is ranked lower than
92% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. ARIA: 2.00 )
Ranked among companies with meaningful Days Payable only.
ARIA' s Days Payable Range Over the Past 10 Years
Min: 431.49  Med: 755.92 Max: 2937.44
Current: 2
431.49
2937.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.27
ARIA's Price/Median PS Value is ranked higher than
90% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. ARIA: 0.27 )
Ranked among companies with meaningful Price/Median PS Value only.
ARIA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 1.21 Max: 119.88
Current: 0.27
0.07
119.88
Price/Graham Number 1.73
ARIA's Price/Graham Number is ranked higher than
58% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. ARIA: 1.73 )
Ranked among companies with meaningful Price/Graham Number only.
ARIA' s Price/Graham Number Range Over the Past 10 Years
Min: 0.17  Med: 1.29 Max: 2.34
Current: 1.73
0.17
2.34
Earnings Yield (Greenblatt) (%) -14.73
ARIA's Earnings Yield (Greenblatt) (%) is ranked lower than
62% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. ARIA: -14.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARIA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -14.89  Med: 25.80 Max: 43.5
Current: -14.73
-14.89
43.5

More Statistics

Revenue(Mil) $119
EPS $ -1.22
Beta1.61
Short Percentage of Float17.15%
52-Week Range $4.37 - 10.07
Shares Outstanding(Mil)191.03

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 209 282 284
EPS($) -0.93 -0.72 -0.81
EPS without NRI($) -0.93 -0.72 -0.81

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300294, SHSE:600161, NAS:NKTR, SZSE:300009, HKSE:00570, ROCO:4174 » details
Traded in other countries:APS.Germany, ARIA.Switzerland, 0R2K.UK,
Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
ARIAD to Webcast Conference Call on First Quarter 2016 Financial Results Apr 26 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Apr 25 2016
ARIAD Announces Results of Preclinical Studies on AP32788 at the Annual Meeting of the American... Apr 19 2016
ARIAD Gains on Updated Brigatinib Phase I/II Study Data Apr 18 2016
ARIAD Presents Updated Phase 1/2 Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell... Apr 15 2016
Why one trader is selling Ariad calls Apr 12 2016
ARIAD Announces Initiation of Randomized, First-Line Phase 3 Trial of Brigatinib in Treatment of... Apr 11 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Mar 29 2016
ARIAD Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review Mar 29 2016
WSJ story features local cancer drug as a success when used off-label Mar 29 2016
Five Cheap Healthcare Stocks With Hedge Fund Support Mar 24 2016
Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX Mar 22 2016
Is Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? Mar 22 2016
ARIAD Reports Inducement Grant to New Chief Financial Officer Mar 22 2016
Ubben Sells More Shares of Motorola Solutions Inc. (MSI), Meister Cuts Stake in This REIT, Plus 2... Mar 21 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 18 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other... Mar 14 2016
Ariad replaces longtime CFO, hires second C-level officer this year Mar 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK